Veloxis Pharma Inc v. Glenmark Pharma Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Veloxis Pharmaceuticals, Inc. (Delaware)
  • Defendant: Glenmark Pharmaceuticals Inc., USA (Delaware)
  • Plaintiff's Counsel: Morris, Nichols, Arsht & Tunnell LLP; Quinn Emanuel Urquhart & Sullivan LLP
• Case Identification: 1:26-cv-00305, D. Del., 03/20/2026
• Venue Allegations: Venue is asserted on the basis that Defendant is incorporated in the State of Delaware and therefore resides in the judicial district.
• Core Dispute: Plaintiff alleges that Defendant's submission of an Abbreviated New Drug Application (ANDA) for generic extended-release tacrolimus tablets constitutes an act of infringement of a patent covering stabilized oral dosage forms of tacrolimus.
• Technical Context: The technology relates to pharmaceutical formulations designed to enhance the stability and bioavailability of tacrolimus, a widely used immunosuppressant drug for preventing organ transplant rejection.
• Key Procedural History: The litigation was initiated under the Hatch-Waxman Act following Defendant's notification to Plaintiff of its ANDA filing with the FDA. This notification included a Paragraph IV certification, asserting that the patent-in-suit is invalid and/or not infringed by the proposed generic product.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,403,095 - "Stabilized Tacrolimus Composition"

• Patent Identification: U.S. Patent No. 12,403,095, "Stabilized Tacrolimus Composition," issued September 2, 2025 ('095 Patent).

The Invention Explained

• Problem Addressed: The patent addresses the challenge that tacrolimus, a potent immunosuppressant, is poorly soluble in water, which can limit its bioavailability when administered orally Compl., Ex. A, '095 Patent, col. 2:24-29 While creating "solid dispersions" can improve solubility, this formulation technique increases the molecular mobility of tacrolimus, making it more susceptible to chemical degradation and the formation of undesirable impurities during storage Compl., Ex. A, '095 Patent, col. 2:47-59
• The Patented Solution: The invention is a pharmaceutical composition that stabilizes tacrolimus within a solid dispersion Compl., Ex. A, '095 Patent, col. 3:11-17 This is achieved by incorporating a "stabilizing agent," such as an organic acid, which is also a metal chelating agent Compl., Ex. A, '095 Patent, col. 8:5-12 This agent provides an acidic microenvironment (a pH below 7) within the composition, which inhibits the formation of a specific major degradation product known as 8-epitacrolimus, thereby enhancing the product's shelf-life (Compl., Ex. A, '095 Patent, col. 4:8-12; Compl., Ex. A, '095 Patent, col. 8:60-64).
• Technical Importance: This technology enables the development of oral tacrolimus formulations that simultaneously offer improved bioavailability (via the solid dispersion) and enhanced chemical stability, a critical combination for ensuring consistent drug delivery, safety, and regulatory compliance Compl., Ex. A, '095 Patent, col. 2:10-23

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 Compl. ¶33
• The essential elements of independent claim 1 include:
  • A pharmaceutical composition comprising a solid dispersion of tacrolimus in a mixture of a vehicle and a stabilizing agent.
  • The stabilizing agent is a metal chelating agent.
  • The stabilizing agent provides a pH below 7 in the composition.
  • The composition comprises from about 0.5% to about 5% of tacrolimus by weight.
  • The composition exhibits a specific stability profile, containing "no more than 0.5% more 8-epitacrolimus" after storage for 5 weeks at 40° C and 75% relative humidity.
  • Tacrolimus is the sole active ingredient in the composition.
  • The vehicle does not include a cyclo-dextrin.
• The complaint alleges infringement of "one or more claims," preserving the option to assert other claims, including dependent claims Compl. ¶33

III. The Accused Instrumentality

Product Identification

• Defendant's proposed 0.75 mg, 1 mg, and 4 mg extended-release tacrolimus tablets, which are the subject of ANDA No. 217905 ("Defendant's ANDA Products") Compl. ¶1

Functionality and Market Context

• The complaint alleges that Defendant's ANDA Products are generic versions of Plaintiff's brand-name drug, ENVARSUS XR® (tacrolimus) Compl. ¶2
• By filing an ANDA, Defendant represents to the FDA that its products have the same active ingredient, dosage form, strengths, and route of administration as ENVARSUS XR® Compl. ¶23 The products are intended to be bioequivalent to ENVARSUS XR® and are intended for the same approved indications: the prophylaxis of organ rejection in kidney transplant patients Compl. ¶19 Compl. ¶23

IV. Analysis of Infringement Allegations

The complaint alleges that Defendant's ANDA Products, and their use according to the proposed label, will infringe at least claim 1 of the '095 Patent Compl. ¶34 The complaint does not contain a claim chart or detailed factual allegations mapping specific components of the accused product to the claim limitations. The core infringement theory rests on the allegation that Defendant's product, as a generic version of ENVARSUS XR®, necessarily practices the claimed invention Compl. ¶2 Compl. ¶34 No probative visual evidence provided in complaint.

'095 Patent Infringement Allegations

Identified Points of Contention

• Scope Questions: A central dispute may concern whether an excipient in Defendant's formulation falls within the scope of a "stabilizing agent that is a metal chelating agent" as construed from the patent. The case will depend on the precise composition of the ANDA product, which will be revealed during discovery.
• Technical Questions: The functional limitation requiring the composition to generate "no more than 0.5% more 8-epitacrolimus" after specific storage conditions raises a key technical question. Infringement will depend on whether empirical testing of Defendant's ANDA product confirms that it meets this stability requirement.

V. Key Claim Terms for Construction

The complaint does not provide sufficient detail for analysis of specific claim terms that may be in dispute. However, based on the patent and the nature of the dispute, certain terms are central.

• The Term: "stabilizing agent"

• Context and Importance: The presence and identity of a "stabilizing agent" is a core requirement of the asserted claim. The outcome of the infringement analysis will likely depend on whether an excipient in Defendant's formulation meets the definition of this term.

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The specification provides a functional definition, stating the agent is useful for "preventing or reducing the formation of tacrolimus degradation products" Compl., Ex. A, '095 Patent, col. 2:8-11 It also provides a list of suitable agents that includes "inorganic acids, inorganic bases, inorganic salts, organic acids, organic bases, and pharmaceutically acceptable salts thereof" Compl., Ex. A, '095 Patent, col. 3:22-29
  • Evidence for a Narrower Interpretation: The specification repeatedly highlights organic acids with metal-chelating properties as preferred embodiments, such as "citric acid, tartaric acid, oxalic acid" Compl., Ex. A, '095 Patent, col. 8:9-11 A defendant may argue that the term should be construed more narrowly to require these specific functionalities, as they are presented as key to solving the stated problem.

• The Term: "solid dispersion"

• Context and Importance: This term defines the physical form of the tacrolimus in the composition. A dispute could arise if Defendant argues its formulation technology achieves stabilization and bioavailability through a means other than a "solid dispersion."

• Intrinsic Evidence for Interpretation:

  • Evidence for a Broader Interpretation: The patent provides a broad definition: "a drug substance or an active ingredient dispersed or dissolved in an inert vehicle, carrier, diluent or matrix in solid state" Compl., Ex. A, '095 Patent, col. 7:56-59
  • Evidence for a Narrower Interpretation: The examples in the patent consistently describe forming the solid dispersion by melting a polymer vehicle, dissolving the tacrolimus, and spraying the mixture onto a substrate to solidify Compl., Ex. A, '095 Patent, col. 15:35-41 Defendant could contend that the term should be limited to compositions formed by such a melt-spray process.

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Defendant will induce infringement by marketing and selling its ANDA Products with instructions for use, knowing such use infringes the '095 Patent Compl. ¶37 It also alleges contributory infringement, asserting that Defendant's products are especially adapted for an infringing use and have no substantial non-infringing use Compl. ¶38
• Willful Infringement: The complaint alleges that Defendant had knowledge of the '095 Patent prior to filing its ANDA, which forms a basis for willfulness Compl. ¶41 This is directly supported by Defendant's submission of a Paragraph IV certification specifically challenging the patent Compl. ¶24

VII. Analyst's Conclusion: Key Questions for the Case

• A central issue will be one of compositional identity: Does the formulation detailed in Defendant's confidential ANDA contain an excipient that functions as a "metal chelating agent" to provide a pH below 7, and does the final product meet the specific, quantified stability requirements of claim 1? This is a primarily factual question that will be resolved through discovery and expert testing.
• A parallel question will be one of validity: Does the prior art teach or suggest using a metal-chelating, pH-lowering agent to solve the specific problem of 8-epitacrolimus formation in solid dispersions of tacrolimus? The case may turn on whether the claimed solution was an obvious step to a person of ordinary skill in the art at the time of the invention, an issue raised by Defendant's Paragraph IV certification Compl. ¶24